Pular para o conteúdo principal
Ranking Invest

ARDX - Ardelyx, Inc.

Segmento: HealthcareArdelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Análise Ranking Invest

Valor de Mercado
$ 805.42 Mi
IVR
-0.10Índice proprietário de comparação relativa: -0,10.
IVR2
-0.27Leitura proprietária complementar: -27%.
MLL
-0.27Leitura proprietária complementar: -27%.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 149.01 Mi

Dívida Líquida

$ 154.63 Mi

L4T

-$ 55.70 Mi

MM4T

-13.71%

Indicadores Básicos

ROE

-37.38%

Índices de Previsibilidade

Receita Líquida

F0.31

Lucro

D0.94

Margem

E1.80

Índices de Tendência

Receita Líquida

A10.70

Lucro

D-1.22

Margem

B4.69

Índices de Endividamento

DIV/PAT

1.04

DIV/L4T

-2.78

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.